Share

    


In This Section

Home / Blurb / Discussion List

FDA Approves Talazoparib for gBRCAm HER2- Breast Cancer

Oct 16, 2018, 11:57 AM
URL:
On October 16, the U.S. Food and Drug Administration approved talazoparib (Talzenna, Pfizer Inc.) for the treatment of patients with deleterious or suspected germline BRCA-mutated (gBRCAm), HER2 negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on the use of the FDA-approved companion diagnostic BRACAnalysis CDx (Myriad Genetics, Inc.).

Read the full FDA press release here.

Posted 10/16/18

Leave a comment